AMAL Therapeutics raises EUR8m in first closing of Series B financing round
AMAL Therapeutics (AMAL), a Swiss biotech developing peptide-based therapeutic cancer vaccines, has completed the first tranche of its Series B financing round, raising EUR8 million (CHF8.8 million). The Company will use the funds to progress its lead vaccine (ATP128) towards clinical studies and proof-of-concept in colorectal cancer. It will also
